MacroGenics’ (MGNX) “Outperform” Rating Reiterated at Wedbush

Wedbush restated their outperform rating on shares of MacroGenics, Inc. (NASDAQ:MGNX) in a report issued on Monday. They currently have a $44.00 price target on the biopharmaceutical company’s stock.

A number of other brokerages have also issued reports on MGNX. Zacks Investment Research upgraded MacroGenics from a sell rating to a hold rating and set a $19.00 target price on the stock in a research report on Tuesday, July 18th. Cowen and Company restated a buy rating on shares of MacroGenics in a report on Friday, August 4th. BidaskClub lowered MacroGenics from a sell rating to a strong sell rating in a report on Saturday, August 12th. Morgan Stanley decreased their price objective on MacroGenics from $22.00 to $21.00 and set an equal weight rating on the stock in a report on Monday, August 7th. Finally, ValuEngine upgraded MacroGenics from a strong sell rating to a sell rating in a report on Friday, September 1st. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $30.30.

MacroGenics (NASDAQ MGNX) opened at 17.12 on Monday. The stock’s market capitalization is $629.98 million. MacroGenics has a 12-month low of $14.36 and a 12-month high of $32.68. The company has a 50-day moving average price of $17.00 and a 200-day moving average price of $18.41.

MacroGenics (NASDAQ:MGNX) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.09). MacroGenics had a negative net margin of 1,216.51% and a negative return on equity of 56.81%. The business had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $15.82 million. During the same quarter last year, the business earned $1.12 EPS. The company’s quarterly revenue was down 97.9% on a year-over-year basis. Analysts expect that MacroGenics will post ($4.42) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “MacroGenics’ (MGNX) “Outperform” Rating Reiterated at Wedbush” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/09/15/macrogenics-mgnx-outperform-rating-reiterated-at-wedbush.html.

A number of hedge funds have recently made changes to their positions in the business. FMR LLC increased its stake in shares of MacroGenics by 6.0% in the 2nd quarter. FMR LLC now owns 5,238,917 shares of the biopharmaceutical company’s stock worth $91,733,000 after acquiring an additional 295,553 shares during the last quarter. OppenheimerFunds Inc. increased its stake in shares of MacroGenics by 9.4% in the 1st quarter. OppenheimerFunds Inc. now owns 3,323,025 shares of the biopharmaceutical company’s stock worth $61,808,000 after acquiring an additional 286,018 shares during the last quarter. BB Biotech AG increased its stake in shares of MacroGenics by 4.0% in the 2nd quarter. BB Biotech AG now owns 2,350,112 shares of the biopharmaceutical company’s stock worth $41,150,000 after acquiring an additional 90,112 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of MacroGenics by 2.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,391,322 shares of the biopharmaceutical company’s stock worth $24,362,000 after acquiring an additional 38,458 shares during the last quarter. Finally, Wasatch Advisors Inc. increased its stake in shares of MacroGenics by 5,159.3% in the 2nd quarter. Wasatch Advisors Inc. now owns 1,044,243 shares of the biopharmaceutical company’s stock worth $18,285,000 after acquiring an additional 1,024,388 shares during the last quarter. Institutional investors own 84.47% of the company’s stock.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Analyst Recommendations for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply